BookMichael R. Migden, Leon Chen, Sirunya Silapunt, editors.
Contents:
Chapter 6: Cryotherapy and Electrodesiccation & Curettage for Basal Cell Carcinoma Intro
Preface
Contents
Contributors
Editor Biographies
Chapter 1: Epidemiology and Risk Factors of Basal Cell Carcinoma
Epidemiology
Introduction
Geography
Demographics
Location and Histologic Subtype
Morbidity and Mortality
Economic Burden
Prevention
Risk Factors
Introduction
UV Radiation
Photosensitizing Medications
Ionizing Radiation
Chemical Exposures
Immunosuppression
Genes
Conclusion
References
Chapter 2: Pathophysiology of Basal Cell Carcinoma and Its Associated Genetic Syndromes
Introduction Basal Cell Nevus Syndrome (BCNS)
Bazex-Dupre-Christol Syndrome
Rombo Syndrome
Additional Genetic Syndromes with Increased Risk of Basal Cell Carcinoma
References
Chapter 3: Histopathology of Basal Cell Carcinoma and Its Variants
Introduction
Common Histologic Features
Histologic Variants
Nodular Basal Cell Carcinoma
Superficial Basal Cell Carcinoma
Infundibulocystic/Hamartomatous Basal Cell Carcinoma
Fibroepithelioma of Pinkus
Infiltrative Basal Cell Carcinoma
Morpheaform Basal Cell Carcinoma
Micronodular Basal Cell Carcinoma Clear Cell Basal Cell Carcinoma
Adenoid Basal Cell Carcinoma
Pleomorphic Basal Cell Carcinoma
Keratotic Basal Cell Carcinoma
Basal Cell Carcinoma with Matrical Differentiation
Basal Cell Carcinoma with Ductal Differentiation
Metaplastic Basal Cell Carcinoma
High-Risk Features
References
Chapter 4: Topical Therapy for the Treatment of Basal Cell Carcinoma
Introduction
Background
Mechanism of Action
Imiquimod
5-Fluorouracil
Ingenol Mebutate
Efficacy
Imiquimod
5-Fluorouracil
Ingenol Mebutate
Safety
Imiquimod
5-Fluorouracil Ingenol Mebutate
Comparative Studies
Imiquimod
Comparison of Different Treatment Regimens of Imiquimod to Vehicle Cream
Comparison of Imiquimod to Other Treatment Modalities
5-Fluorouracil
Ingenol Mebutate
Emerging Topical Treatments and Combination Therapies
Combination Therapies
Imiquimod Plus CT
Imiquimod Plus PDT
Imiquimod Plus Curettage
Imiquimod Plus MMS
5-FU Combination Therapy
Discussion and Conclusions
References
Chapter 5: Local Immunotherapy for Basal Cell Carcinoma with Interferon
Introduction
Background Role of the Immune System
Treatment with Immunostimulatory Agents (ISRX)
Efficacy
Low Recurrence Rate
Normal Skin Markings
Cosmesis
Preservation of Function
No Wound
All Other Therapeutic Options Remain Open
Disadvantages of ISRX
Mechanism of Action of ISRX
Patient/Tumor Selection
Interferon Injections
Preparation of IFN for Injection
Injection Technique
Dosage of IFN
Combination of IFN with IMIQ
Side Effects
Recommended Follow-Up for BCC Treated with ISRX
Conclusion
References